Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Antimicrob Chemother. 2018 Jun 1;73(6):1439-1451. doi: 10.1093/jac/dkx543.

Clinical review of delafloxacin: a novel anionic fluoroquinolone.

Author information

1
Department of Pharmacy, Upstate Medical University Hospital, Syracuse, NY, USA.
2
Department of Pharmacology, Upstate Medical University, Syracuse, NY, USA.
3
Division of Infectious Diseases, Upstate Medical University, Syracuse, NY, USA.
4
Department of Microbiology and Immunology, Upstate Medical University, Syracuse, NY, USA.
5
Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA.
6
Department of Medicine, Upstate Medical University, Syracuse, NY, USA.

Abstract

Delafloxacin is a novel anionic fluoroquinolone (FQ) approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by a number of Gram-positive and Gram-negative organisms including MRSA and Pseudomonas aeruginosa. The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in acidic environments. In Phase III studies, delafloxacin had similar outcomes to comparator regimens for treatment of ABSSSIs, and was well tolerated overall. Similar to other FQs, delafloxacin is available in both intravenous and oral formulations, but differs in that delafloxacin exerts a minimal effect on cytochrome P450 enzymes and on the corrected QT interval. This novel FQ has the potential to be utilized across a wide variety of clinical settings; however, post-marketing surveillance and long-term safety and resistance data will be essential to identify optimal use scenarios.

PMID:
29425340
DOI:
10.1093/jac/dkx543

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center